Paul Choi
Stock Analyst at Goldman Sachs
(3.21)
# 961
Out of 5,182 analysts
107
Total ratings
50.72%
Success rate
1.62%
Average return
Main Sectors:
Stocks Rated by Paul Choi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRVS Corvus Pharmaceuticals | Initiates: Buy | $40 | $15.19 | +163.33% | 1 | Apr 17, 2026 | |
| RGNX REGENXBIO | Maintains: Neutral | $14 → $12 | $8.97 | +33.78% | 4 | Feb 10, 2026 | |
| VERA Vera Therapeutics | Maintains: Buy | $55 → $95 | $35.61 | +166.78% | 1 | Dec 19, 2025 | |
| CYTK Cytokinetics | Upgrades: Buy | $55 → $95 | $63.97 | +48.51% | 3 | Dec 19, 2025 | |
| PTCT PTC Therapeutics | Maintains: Sell | $44 → $50 | $65.06 | -23.15% | 8 | Nov 5, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $55 → $100 | $71.11 | +40.63% | 7 | Oct 31, 2025 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Buy | $45 → $55 | $53.78 | +2.27% | 2 | Oct 29, 2025 | |
| ARVN Arvinas | Downgrades: Sell | $8 → $6 | $9.90 | -39.39% | 4 | Oct 15, 2025 | |
| LNTH Lantheus Holdings | Downgrades: Neutral | $110 → $77 | $84.62 | -9.00% | 2 | Oct 8, 2025 | |
| EWTX Edgewise Therapeutics | Initiates: Neutral | $20 | $30.96 | -35.40% | 1 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $47 | $44.46 | +5.71% | 1 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $7 → $12 | $13.93 | -13.85% | 9 | Jun 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $16 → $3 | $23.83 | -87.41% | 4 | May 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $8 | $0.37 | +2,075.10% | 6 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $5 | $11.20 | -55.36% | 10 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $52 | $56.04 | -7.21% | 2 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $21 | $10.22 | +105.58% | 8 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $3 | $2.00 | +50.00% | 9 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $225 | $229.38 | -1.91% | 4 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $19 | $13.45 | +41.26% | 6 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $19 | $4.75 | +300.00% | 3 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $25 | $1.39 | +1,698.56% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $151 → $170 | $9.59 | +1,672.68% | 2 | Oct 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $9 → $8 | $7.51 | +6.52% | 4 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $135 | $131.67 | +2.53% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $270 → $300 | $85.04 | +252.78% | 2 | Mar 30, 2020 |
Corvus Pharmaceuticals
Apr 17, 2026
Initiates: Buy
Price Target: $40
Current: $15.19
Upside: +163.33%
REGENXBIO
Feb 10, 2026
Maintains: Neutral
Price Target: $14 → $12
Current: $8.97
Upside: +33.78%
Vera Therapeutics
Dec 19, 2025
Maintains: Buy
Price Target: $55 → $95
Current: $35.61
Upside: +166.78%
Cytokinetics
Dec 19, 2025
Upgrades: Buy
Price Target: $55 → $95
Current: $63.97
Upside: +48.51%
PTC Therapeutics
Nov 5, 2025
Maintains: Sell
Price Target: $44 → $50
Current: $65.06
Upside: -23.15%
BridgeBio Pharma
Oct 31, 2025
Maintains: Buy
Price Target: $55 → $100
Current: $71.11
Upside: +40.63%
Kiniksa Pharmaceuticals International,
Oct 29, 2025
Maintains: Buy
Price Target: $45 → $55
Current: $53.78
Upside: +2.27%
Arvinas
Oct 15, 2025
Downgrades: Sell
Price Target: $8 → $6
Current: $9.90
Upside: -39.39%
Lantheus Holdings
Oct 8, 2025
Downgrades: Neutral
Price Target: $110 → $77
Current: $84.62
Upside: -9.00%
Edgewise Therapeutics
Sep 25, 2025
Initiates: Neutral
Price Target: $20
Current: $30.96
Upside: -35.40%
Sep 17, 2025
Initiates: Buy
Price Target: $47
Current: $44.46
Upside: +5.71%
Jun 25, 2025
Maintains: Sell
Price Target: $7 → $12
Current: $13.93
Upside: -13.85%
May 22, 2025
Maintains: Neutral
Price Target: $16 → $3
Current: $23.83
Upside: -87.41%
May 16, 2025
Maintains: Buy
Price Target: $7 → $8
Current: $0.37
Upside: +2,075.10%
May 2, 2025
Maintains: Neutral
Price Target: $10 → $5
Current: $11.20
Upside: -55.36%
Apr 17, 2025
Maintains: Buy
Price Target: $60 → $52
Current: $56.04
Upside: -7.21%
Apr 17, 2025
Maintains: Buy
Price Target: $28 → $21
Current: $10.22
Upside: +105.58%
Apr 17, 2025
Maintains: Neutral
Price Target: $4 → $3
Current: $2.00
Upside: +50.00%
Feb 13, 2025
Maintains: Buy
Price Target: $200 → $225
Current: $229.38
Upside: -1.91%
Aug 1, 2024
Maintains: Neutral
Price Target: $17 → $19
Current: $13.45
Upside: +41.26%
Jun 29, 2023
Maintains: Buy
Price Target: $21 → $19
Current: $4.75
Upside: +300.00%
May 24, 2022
Maintains: Buy
Price Target: $43 → $25
Current: $1.39
Upside: +1,698.56%
Oct 6, 2021
Maintains: Buy
Price Target: $151 → $170
Current: $9.59
Upside: +1,672.68%
Aug 6, 2021
Maintains: Sell
Price Target: $9 → $8
Current: $7.51
Upside: +6.52%
Jun 29, 2020
Downgrades: Neutral
Price Target: $135
Current: $131.67
Upside: +2.53%
Mar 30, 2020
Upgrades: Neutral
Price Target: $270 → $300
Current: $85.04
Upside: +252.78%